The interaction of host proteins with lentiviruses and other retroviruses and retrotransposons represents a major research theme of the Rowley lab. The proposed work fits well with the mission of the NIH and is a field of study that has traditionally been well supported. Dr. Rowley is fully committed to providing all the necessary support for the development of the molecular models and the production of supporting experimental data. Investigating the complex interactions that occur between the capsid protein of primate lentiviruses (including HIV) and human proteins, to understand the consequences of host evolution on viral replication. Then to identify key determinants of lentivirus-primate interaction, specifically between the Nup153p capsid-interacting motif and the HIV-1 capsid. Use known crystal structures as templates for modeling the polymorphisms present within Nup153 variants.
What’s your COVID-19 exposure risk in a gathering?November 24, 2020
Thank you to reporter Kyle Pfannenstiel for highlighting some of U of I’s COVID-19 modeling efforts, as originally published in the Post Register. If you’ll be at the dinner table with people you don’t live with this week, research from the University of Idaho can help you gauge how likely you are to bump into someone who […]
It Takes a Village (and a Research University)November 20, 2020
This article was written by Alexiss Turner, Marketing and Communications Manager from the College of Engineering, for the recently published “Here We Have Idaho” magazine. IMCI and many of our faculty participants have been very involved in the COVID-19 pandemic response. We are proud to be part of the many research efforts campus-wide that continue […]
University of Idaho Receives Grant of Nearly $11M for Biomedical Research ModelingAugust 13, 2020
MOSCOW, Idaho — Aug. 13, 2020 — The University of Idaho has secured a grant of nearly $11 million from the National Institutes of Health to support continued modeling for biomedical research at U of I’s Institute for Modeling Collaboration and Innovation (IMCI). The funding comes as Phase 2 of a Centers of Biomedical Research Excellence (COBRE) grant […]